# Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

> **NCT00416494** · PHASE2 · COMPLETED · sponsor: **Herbert Hurwitz, MD** · enrollment: 50 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00416494
- **Lead sponsor:** Herbert Hurwitz, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2008-01
- **Final completion:** 2014-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00416494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00416494, "Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00416494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*